Alterity Therapeutics (ATH) KOL event summary

Introduction and agenda

• Event focused on ATH434 for multiple system atrophy (MSA), featuring clinical experts and company leadership.

• Agenda included disease overview, phase II data insights, phase III planning, and regulatory updates.

• Q&A session followed the formal presentations.

KOL background and credentials

• Dr. Roy Freeman: Professor of Neurology at Harvard, expert in autonomic neurology and MSA.

• Dr. Daniel Claassen: Professor of Neurology at Vanderbilt, key contributor to clinical and neuroimaging aspects of the program.

Market insights and analysis

• MSA is a rare, progressive neurodegenerative disease with no approved disease-modifying therapies.

• Significant unmet need and commercial opportunity due to lack of approved treatments targeting underlying pathology.

• Orphan drug and Fast Track designations in the US and Europe enhance regulatory and commercial prospects.